Referring to the drawings, to the following detailed description, and to incorporated materials, detailed information about the invention is provided including the description of specific embodiments. The detailed description serves to explain the principles of the invention. The invention is susceptible to modifications and alternative forms. The invention is not limited to the particular forms disclosed. The invention covers all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the claims.
Beryllium is used in many industries in a variety of forms—most commonly metal, oxides and alloys for the manufacture of materials ranging from nuclear components and electronics to golf clubs and aircraft brakes. During the machining of beryllium parts, a range of beryllium particle sizes may be dispersed and pose a threat to worker health. When inhaled, the beryllium particles are taken into the lungs and trapped in the alveoli and it is felt that such particles can contribute to a lung burden of beryllium, which can slowly dissolve to provide an immunologic challenge to the lungs.
Once in the lung tissue, the beryllium particles trigger the cell-mediated immune response, resulting in lymphocytic inflammation and eventually granulomatous lung scarring, termed Chronic Beryllium Disease (CBD). The current treatment for CBD is Prednisone, which acts to inhibit the inflammatory and immune response to beryllium. However, the use of such treatment is also associated with side effects including susceptibility to infections, water retention and loss of bone density.
The present invention provides a method of chelation therapy that includes applying α-aminobenzyl-α,α,-diphosphoric acid to treat Chronic Beryllium Disease. Chelation therapy could eventually provide an alternative or adjunctive treatment for the removal of a beryllium lung burden, therefore reducing immunologic challenge by beryllium, beryllium-related lymphocyte proliferation and potentially slowing the development of CBD. The goal of chelation therapy of metals is to selectively bind with the toxic metal ion and excrete the metal-chelate complex from the body. Ideally, this would be performed selectively such that only the toxic metal is bound while leaving other essential metals intact.
Chelator Selection:
Over 200 potential chelators in the NIST Critically Reviewed Thermodynamic Database were screened and ranked on their ability to both dissolve beryllium and maintain binding over a ‘reasonable’ pH range typically seen in the body. Modeling was performed again using the MINTEQA2 code. Solubility data was plotted in a contour format to show the effect of both pH and chelator concentration on beryllium solubility. Speciation diagrams were plotted showing the effect of chelator concentration on beryllium binding, and hence examining the effectiveness and selectiveness of the chelator. The results showed that α-aminobenzyl-α,α,-diphosphoric acid (APMDP) was the most selective and effective beryllium chelator.
Chelator Toxicology:
α-aminobenzyl-α,α,-diphosphoric acid—This compound has no reported LD-50 data in the “Registry of Toxic Effects of Chemical Substances.” It possesses a high degree of polarity. Benzylamine is reasonable toxic (LD-50 of 128 mg/Kg) possibly due to metabolic interference with catecholamine biosynthesis. Substitution of alkyl groups near the amine appears to reduce the toxicity of the benzyl-amine (e.g., a-methylbenzylamine LD-50 940 mg/Kg). Substitution of alkyl groups on the amine increase the toxicity of benzylamines by reducing water solubility and increasing membrane permeability (e.g., N,N-dimethyl-a-methylbenzylamine, LD-50 420 mg/Kg). In contrast, phenylphosphonic acid is water soluble, yet toxic at 110 mg/Kg possibly due to its stronger acid properties. Therefore, with this toxicology data, the questioned molecule (a,a-diphosphonylbenzylamine) which possesses both functionalities (ct-substituted benzylamine and two phosphonic acids) in the same molecule, may exhibit an LD-50 in the range of 400 mg-900 mg/Kg.
Chelator Synthesis:
α-aminobenzyl-α,α,-diphosphoric acid was synthesized according to a previously described procedure: Patent: Lerch, I.; Kottler, A. Experiments in the production of α-primary amino phosphoric acids and their esters; DE 1002355; 1954. Characterization: 1H NMR (D2O, 500 MHz) δ=7.10-7.25 (m, 3H); 7.30-7.50 (m, 2H): 13C NMR (CDCl3, 125 MHz) δ=63.6 (JCP=125 Hz), 127.3, 129.3, 130.0, 134.7: 31P NMR (CDCl3, 202 MHz) δ=10.6: elemental analysis calculated (%) for C7H15NO8P2.2H2O (303.0) C, 27.70; H, 4.99; N., 4.62, P 20.44: found C, 27.97; H, 5.04; N., 5.42, P 20.05.
Animal Chelator Experiments:
LLNL-IBC#2004-029. Two sets of animal experiments were performed. Firstly, a smaller group of mice were exposed to beryllium, APMDP and another proven beryllium chelator (tiron), to allow a study of the effect on mice—clearly, if APMDP or the administration of beryllium or tiron were found to be harmful to the mice using our method, we would need to know using a smaller mouse group. The initial results showed that beryllium and chelator administration did not adversely affect the mice over the course of the 48-hour experiment.
Mice (˜30 g) were given 0.05 mg beryllium per kg followed by the chosen chelator (at 1× Be, 5× Be and 10× Be) 12 hours post-beryllium exposure. Urine samples were taken every 12 hours and tissue samples were excised after termination at 72 hours. Samples were analyzed for beryllium by ICP-MS. The experiment showed that beryllium burden in tissue (lung, liver, kidney, and spleen) was decreased and beryllium urinary excretion was increased compared to the control mice.
Examples—Chelation Therapy of Patient Suffering from Chronic Beryllium Disease
Examples of beryllium chelation therapy include
Persons suspected or proven exposed to beryllium by inhalation.
Persons proven beryllium-sensitized.
Persons showing prognosis of Chronic Beryllium Disease.
Persons proven to have skin, ingestion or wound beryllium contamination (here, administration may be different to that listed above; for skin/wound contamination—irrigate site with α-aminobenzyl-α,α,-diphosphoric acid; for ingestion of solid beryllium, give interperitoneal injection of α-aminobenzyl-α,α,-diphosphoric acid); for inhalation of solid beryllium, give lung-lavage, interperitoneal or subcutaneous injections of α-aminobenzyl-α,α,-diphosphoric acid).
An example of chelation therapy of a patient suffering from Beryllium Sensitization or chronic beryllium disease includes the steps of administering α-aminobenzyl-α,α,-diphosphoric acid to the patient. The most effective method of administering α-aminobenzyl-α,α,-diphosphoric acid may is by lung-lavage. The next step is α-aminobenzyl-α,α,-diphosphoric acid given by ingestion, or subcutaneous/interperitoneal injection. The next step is allowing chelation of the beryllium for reduction of beryllium lung burden in the patient. This allows reduction of beryllium lung and/or body-burden which reduces or ceases progression of Beryllium Sensitization and Chronic Beryllium Disease. The beryllium excretion in the patient is monitored in urine during and following the administration of α-aminobenzyl-α,α,-diphosphoric acid.
Environmental Remediation—Examples of Environmental Remediation include:
Removal of beryllium oxide from Site-300 explosive tests inside CFF and outside on firing tables and earth.
Removal of beryllium solids and liquids from contaminated beryllium-manufacturing and machining sites.
Removal of beryllium solids and liquids from contaminated electronic waste sites (so-called “e-waste”).
For solid beryllium remediation, a preferred method is to wash, soak or rinse the contaminated area with α-aminobenzyl-α,α,-diphosphoric acid, collecting the washes. This is ideal for machine tools, work surfaces etc., but not practical for larger environmental areas such as fields or roads. In the latter case, the more appropriate method would be to use a gel, foam or strippable coating that could be pulled away from the surface by hand, by mechanical means, or by vacuum. Similarly, for liquid contamination, solid material containing α-aminobenzyl-α,α,-diphosphoric acid such as gel, foam or strippable coating would trap the beryllium contamination, preventing further spread. Again the gel, foam and/or coating could be mechanically removed. In addition, the α-aminobenzyl-α,α,-diphosphoric acid may be incorporated into a solid-support matrix (e.g., styrene beads, silica beads or even silica aerogel) and beryllium contaminated liquids could be flowed over the surface (e.g., as in water purification system) to remove beryllium. This latter example would be useful for removing liquid beryllium from liquid environments such as drinking water, sewer water or seawater. The cleaned water may then be recycled.
Selective chelators for beryllium in biological systems are also successful in environmental systems. A selective beryllium chelator allows efficient clean-up of beryllium contamination and allows work to resume on a shorter timescale.
Example of Site-300 Beryllium Particle Chelation
The aims of this investigation were not limited to the study of beryllium in biological fluids and systems. A good chelator in the body is likely a good chelator in the environment. To prove the effectiveness of our chelator on environmental samples, and to prove that chelation could in fact dissolve and bind beryllium oxide, we investigated the effect of APMDP on BeO debris from a test shot at the LLNL Site 300 Contained Firing Facility (CFF). Particles were obtained from the Contained Firing Facility (CFF) at LLNL Site 300. Approximately 500 mg of beryllium oxide debris was weighed in a tared polyethylene vials and varying concentrations of APMDP chelator (pH adjusted to pH 7) were added to each vial. The vials were left to stand for 3 days, with manual shaking performed for 2 minutes each, twice a day. Samples were then filtered through a 0.2 um membrane and filtrates were analyzed by ICP-MS. The results clearly demonstrate a linear concentration profile, indicating that APMDP dissolves and binds beryllium (in this case) at a 1:1 ratio at pH 7. While samples were equilibrated for 3 days, the results indicate that insoluble BeO fines can be dissolved by APMDP chelator.
While the invention may be susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and have been described in detail herein. However, it should be understood that the invention is not intended to be limited to the particular forms disclosed. Rather, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the following appended claims.
This application claims the benefit of U.S. Provisional Patent Application No. 60/795,899 filed Apr. 27, 2006 and titled “a-Aminobenzyl-alpha,alpha,-diphosphoric Acid Selective Chelation of Beryllium in Mice and Environmental Debris.” U.S. Provisional Patent Application No. 60/795,899 filed Apr. 27, 2006 and titled “a-Aminobenzyl-alpha,alpha,-diphosphoric Acid Selective Chelation of Beryllium in Mice and Environmental Debris” is incorporated herein by this reference.
The United States Government has rights in this invention pursuant to Contract No. W-7405-ENG-48 between the United States Department of Energy and the University of California for the operation of Lawrence Livermore National Laboratory.
Number | Date | Country | |
---|---|---|---|
60795899 | Apr 2006 | US | |
60795899 | Apr 2006 | US |